New drug APAC aims to prevent blood clots in leg artery patients

NCT ID NCT07352800

Recruiting now Disease control Sponsor: Aplagon Oy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called APAC, which is designed to prevent blood clots in people with blocked leg arteries. The trial includes 42 adults with peripheral arterial disease or chronic limb-threatening ischemia. Researchers will check if APAC is safe and well-tolerated, and compare different doses to standard care or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APAC (a heparin-like drug to prevent blood clots)
What this could lead to: If successful, this could lead to a new treatment option to prevent blood clots and improve outcomes for patients with severe leg artery disease.
What could go wrong: This is an early Phase 2 trial with only 42 participants, so results may not apply to everyone. The drug may cause side effects or not work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIMB-THREATENING ISCHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Limb-Threatening Ischemia limb ischemia peripheral arterial disease peripheral arterial occlusive disease 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LIMB-THREATENING ISCHEMIA PERIPHERAL ARTERIAL OCCLUSIVE DISEASE

Contacts and locations

Locations

Helsinki University Hospital
RECRUITING

Helsinki, 00290, Finland
Tampere University Hospital
RECRUITING

Tampere, Finland
Turku University Hospital
RECRUITING

Turku, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.